The present study represents the first to use the shRNA approach to simultaneously and specifically knock down the MAPK and PI3K/Akt signaling in cancer cells, definitely demonstrating the therapeutic potential of dually targeting the two pathways for cancers, such as melanoma. The gene discussed is AKT1; the disease is cancer.